sur TuHURA Biosciences, Inc.
TuHURA Biosciences Appoints Dr. Craig L. Tendler to Board
TuHURA Biosciences, Inc., a Phase 3 immuno-oncology company, has appointed Dr. Craig L. Tendler to its Board of Directors. Dr. Tendler brings extensive experience from his previous role as Vice President at Johnson & Johnson, where he oversaw 30 major drug approvals, including treatments for various cancers. His expertise in oncology drug development will be valuable as TuHURA progresses its IFx-2.0 immunotherapy candidate through clinical trials.
Dr. Tendler is recognized for achieving FDA Breakthrough Designations and global approvals for a range of oncology therapies. His background will support TuHURA’s strategy in overcoming resistance to cancer immunotherapy. With this new appointment, TuHURA aims to enhance its development programs and explore future collaborations and acquisitions.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de TuHURA Biosciences, Inc.